The New York-based investment arm of Access Industries, Access Biotechnology, focuses on funding transformative therapies for conditions with high unmet needs that can significantly impact human health. Their investments span across therapeutic areas, modalities, and development stages, from discovery-stage technology platforms to late-stage clinical programs. Established in 2019, the healthcare venture capital group seeks to invest in pre-clinical and clinical companies developing therapeutic platforms and products that address serious unmet clinical needs.